PMID- 31366498
OWN - NLM
STAT- MEDLINE
DCOM- 20190807
LR  - 20211204
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 8
DP  - 2019 Aug
TI  - P53/MDM2 Co-Expression in Laryngeal Squamous Cell Carcinoma Based on Digital 
      Image Analysis.
PG  - 4137-4142
LID - 10.21873/anticanres.13572 [doi]
AB  - BACKGROUND: P53 is a key regulator of genomic stability and function, acting as a 
      tumor suppressor protein. Our aim was to correlate P53 expression with murine 
      double minute 2 (MDM2), a proto-oncogene that interacts with P53 and forms an 
      auto-regulatory pathway, in laryngeal squamous cell carcinoma (LSCC). MATERIALS 
      AND METHODS: A total of 50 LSCC cases were included in the study. 
      Immunohistochemistry was applied by using antibodies to P53 and MDM2 in the 
      corresponding tissue sections. Protein expression levels for both molecules were 
      measured by implementing a digital image analysis assay (immunostaining intensity 
      levels, densitometric evaluation). RESULTS: Overexpression of P53 protein was 
      observed in 16/50 (32%) LSCC cases, while 22/50 (44%) cases strongly expressed 
      MDM2 protein. Interestingly, in 13/50 (26%) cases, combined overexpression of 
      P53/MDM2 was detected. Overall P53 was strongly positively correlated with MDM2 
      expression (p=0.001). Both P53 and MDM2 overexpression were significantly 
      correlated with advanced stage of LSCC (p=0.032 and p=0.001, respectively). 
      Additionally, MDM2 was found to be associated with poorer survival of patients 
      (p=0.046). CONCLUSION: Aberrant co-expression of P53 and MDM2 is associated with 
      advanced stage in LSCC. Furthermore, MDM2 overexpression is a frequent and 
      critical genetic event in LSCC and seems to negatively affect survival.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Chrysovergis, Aristeidis
AU  - Chrysovergis A
AD  - First Department of Otorhinolaryngology, Head and Neck Surgery, Hippocration 
      Hospital, University of Athens, Athens, Greece.
FAU - Papanikolaou, Vasileios
AU  - Papanikolaou V
AD  - First Department of Otorhinolaryngology, Head and Neck Surgery, Hippocration 
      Hospital, University of Athens, Athens, Greece.
FAU - Tsiambas, Evangelos
AU  - Tsiambas E
AD  - Department of Immunohistochemistry and Molecular Biology, 401 General Army 
      Hospital, Athens, Greece tsiambasecyto@yahoo.gr.
FAU - Stavraka, Chara
AU  - Stavraka C
AD  - Department of Medical Oncology, Guy's and St Thomas NHS Foundation Trust, London, 
      U.K.
FAU - Ragos, Vasileios
AU  - Ragos V
AD  - Department of Maxillofacial, Medical School, University of Ioannina, Ioannina, 
      Greece.
FAU - Peschos, Dimitrios
AU  - Peschos D
AD  - Department of Physiology, Medical School, University of Ioannina, Ioannina, 
      Greece.
FAU - Psyrri, Amanda
AU  - Psyrri A
AD  - Section of Medical Oncology, Department of Internal Medicine, Faculty of 
      Medicine, National and Kapodistrian University of Athens, Attikon University 
      Hospital, Athens, Greece.
FAU - Mastronikolis, Nicholas
AU  - Mastronikolis N
AD  - Department of Otorhinolaryngology, Medical School, University of Patras, Patras, 
      Greece.
FAU - Kyrodimos, Efthymios
AU  - Kyrodimos E
AD  - First Department of Otorhinolaryngology, Head and Neck Surgery, Hippocration 
      Hospital, University of Athens, Athens, Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (MAS1 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Carcinoma, Squamous Cell/*diagnostic imaging/drug therapy/genetics/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*diagnostic imaging/drug therapy/genetics/pathology
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - Neoplasm Proteins/genetics
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins c-mdm2/*genetics
MH  - Tumor Suppressor Protein p53/*genetics
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - Larynx
OT  - MDM2
OT  - P53
OT  - carcinoma
OT  - digital image analysis
OT  - immunohistochemistry
EDAT- 2019/08/02 06:00
MHDA- 2019/08/08 06:00
CRDT- 2019/08/02 06:00
PHST- 2019/05/21 00:00 [received]
PHST- 2019/06/19 00:00 [revised]
PHST- 2019/06/20 00:00 [accepted]
PHST- 2019/08/02 06:00 [entrez]
PHST- 2019/08/02 06:00 [pubmed]
PHST- 2019/08/08 06:00 [medline]
AID - 39/8/4137 [pii]
AID - 10.21873/anticanres.13572 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 Aug;39(8):4137-4142. doi: 10.21873/anticanres.13572.